Clinical trial landscape brief
A fixed-scope brief built from the public trial registries. You name the target, mechanism or indication; we confirm the scope in writing within one working day and deliver the brief within five, with one round of questions included.
Typical questions
- Which interventional trials are registered for this target, mechanism or indication, at what phase, with which sponsors and in what status?
- When are the next readouts due, judging from primary completion dates?
- How do the pivotal trials compare on their endpoints?
- What have recent toplines and regulatory filings changed, and what remains open?
What you receive
- 1All registered interventional trials by phase, sponsor and status, from ClinicalTrials.gov and the EU Clinical Trials Register
- 2A readout calendar derived from primary completion dates
- 3Endpoint comparison across the pivotal trials
- 4Recent catalysts, including toplines and regulatory filings, each with its source
- 5An implications section, with open questions marked as such
Well suited to
Biotech business development and strategy teams, life-science investors conducting diligence, and consultancies and CROs preparing proposals.
Every brief is reviewed by one of the named experts before delivery. It is expert analysis of public information, not medical, regulatory, legal or investment advice.
Sample brief
Lipoprotein(a) after HORIZON
An example of the brief, prepared from public sources on 6 October 2026, one month after pelacarsen missed its outcome endpoint. It covers all 18 registered trials of the five lead Lp(a) agents, a readout calendar to 2031, a side-by-side of the four outcome-trial endpoints and 14 cited sources. Sample briefs are in English.
Read the sample brief (PDF, 9 pages)